RespireRx Pharmaceuticals, Inc. (RSPI)
Stock Price:
$0.0054 USD
-0.0020 (-27.03%)
Updated Oct 21, 2020 9:45 AM EDT - Market open
Key Info
| Market Cap |
585,171 |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-2.86M |
| Shares Out |
108.37M |
| EPS (ttm) |
-0.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$0.0054 |
| Previous Close |
$0.0074 |
| Change ($) |
-0.0020 |
| Change (%) |
-27.03% |
| Day's Open |
0.0045 |
| Day's Range |
0.0040 - 0.0054 |
| Day's Volume |
9,045,644 |
| 52-Week Range |
0.0033 - 0.4 |
More Stats
| Market Cap |
585,171 |
| Enterprise Value |
1.94M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
108.37M |
| Float |
63.20M |
| EPS (basic) |
-0.43 |
| EPS (diluted) |
-0.11 |
| FCF / Share |
0.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1,261 |
| Short Ratio |
1.45 |
| Short % of Float |
0.00% |
| Beta |
0.44 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
-1.98M |
| Net Income |
-2.86M |
| Free Cash Flow |
-327,915 |
| Net Cash |
-1.35M |
| Net Cash / Share |
-0.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-1,050.34% |
| ROE |
n/a |
| ROIC |
38.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
97.5
Current: $0.0054
High
97.5
Target: 97.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | 0.09 | 0.06 | - | 0.05 | 3.11 | 10.47 |
| Revenue Growth | - | - | - | - | 40.94% | - | - | -98.45% | -70.26% | - |
| Gross Profit | - | - | - | - | 0.09 | 0.06 | - | 0.05 | 3.11 | 10.47 |
| Operating Income | -1.74 | -2.18 | -4.25 | -8.47 | -5.24 | -4.35 | -1.14 | -7.34 | -2.25 | 2.18 |
| Net Income | -2.12 | -2.59 | -4.29 | -9.23 | -5.96 | -2.71 | -1.20 | -7.57 | -2.26 | 1.63 |
| Shares Outstanding | 3.91 | 3.35 | 2.42 | 1.86 | 1.18 | 0.59 | 0.44 | 0.33 | 0.25 | 0.23 |
| Earnings Per Share | -0.54 | -0.77 | -1.77 | -4.95 | -5.05 | -22.73 | -3.25 | -12.99 | -9.74 | 6.49 |
| Operating Cash Flow | -0.49 | -0.43 | -0.70 | -1.33 | -1.30 | -0.89 | -0.18 | -1.86 | -1.94 | 1.34 |
| Capital Expenditures | - | - | - | - | - | -0.02 | - | - | 0.04 | 0.01 |
| Free Cash Flow | -0.49 | -0.43 | -0.70 | -1.33 | -1.30 | -0.90 | -0.18 | -1.86 | -1.89 | 1.35 |
| Cash & Equivalents | 0.02 | 0.03 | 0.08 | 0.09 | 0.05 | 0.16 | 0.01 | 0.15 | 1.66 | 3.19 |
| Total Debt | 1.63 | 1.25 | 1.15 | 1.29 | 0.86 | 0.58 | 0.60 | 0.47 | - | - |
| Net Cash / Debt | -1.62 | -1.22 | -1.06 | -1.20 | -0.81 | -0.41 | -0.58 | -0.31 | 1.66 | 3.19 |
| Assets | 0.05 | 0.12 | 0.19 | 0.23 | 0.15 | 0.40 | 0.05 | 0.20 | 1.82 | 3.57 |
| Liabilities | 7.49 | 5.86 | 4.55 | 5.73 | 3.01 | 2.60 | 4.24 | 3.19 | 1.14 | 1.16 |
| Book Value | -7.44 | -5.73 | -4.36 | -5.49 | -2.86 | -2.20 | -4.19 | -2.99 | 0.68 | 2.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
RespireRx Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Timothy Jones |
Stock Information
| Ticker Symbol |
RSPI |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: RSPI |
Description
RespireRx Pharmaceuticals engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. It has two drug platforms comprising ampakines, which are small molecule compounds to enhance the excitatory actions of the neurotransmitter glutamate at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complex; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is headquartered in Glen Rock, New Jersey.